China clinical trials are attracting international drugmakers seeking faster patient recruitment and lower costs, while raising questions about safety oversight and transparency. China accounted for 45% of new clinical trials for innovative medicines in 2025, according to pharmaceutical data provider Norstella. Its share stood below 5% in 2008. Meanwhile, McKinsey estimates that Phase 1 costs per patient in China are…
Tag: Drug Development
-
AI Alternatives To Animal Testing Gain Momentum
Millions of animals are used worldwide to test medicines, chemicals and cosmetics. Mice, rats, rabbits, dogs and primates may experience pain or distress during these experiments. Animal testing has traditionally been defended as necessary to protect human health. However, advances in artificial intelligence are challenging that argument. Machine-learning systems can now predict drug toxicity, organ damage and chemical hazards. In…
-
Chinese Pharmaceutical Innovation Impacts Healthcare Landscape
The traditional pharmaceutical order, once anchored in Western centres, has fundamentally shifted. We now inhabit a bipolar industry landscape dominated by the United States and China. This transformation carries significant implications for patients, investors, and policymakers worldwide. Chinese Pharmaceutical Innovation Drives Global Research Boom China has rapidly closed the gap in medical research. In several key areas, it has now…
-
Daraxonrasib Pancreatic Cancer Results: A Historic Breakthrough
Every so often, a medical advance is so significant that it gives seasoned oncologists chills. This is currently the case for Revolution Medicines and their experimental therapy, daraxonrasib. In a recent late-stage study, the drug allowed patients with advanced disease to live twice as long as those receiving standard chemotherapy. For a field where progress is often measured in mere…
-
Animal Testing Alternatives: New FDA Guidance Insights
US regulators are stepping up efforts to reduce animal use in early drug development. On 18 March 2026, the US Food and Drug Administration issued draft guidance encouraging companies to swap or reduce animal studies where credible human-relevant tools exist. This marks an important recognition of the growing range of animal testing alternatives available to researchers. The FDA says a…